Biodesix to Participate in Two Investor Conferences in June

Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William

BusinesswireMay 28 05:00

Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema.

Business WireMay 21 05:00

Biodesix Initiated at Buy by TD Cowen

Biodesix Initiated at Buy by TD Cowen

Dow JonesMay 13 06:36

Biodesix (BDSX.US) was first covered by TD Cowen, which gave it a buy rating, with a target price of $2.80.

Biodesix (BDSX.US) was first covered by TD Cowen, which gave it a buy rating, with a target price of $2.80.

Zhitong FinanceMay 13 06:32

Biodesix Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 68.67% TD Cowen → $2.8 Initiates Coverage On → Buy 05/03/2024 80.72% Lake Street → $3 Initiates

BenzingaMay 13 06:25

TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target

TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target.

MT NewswiresMay 13 06:07